A5020209844- Inflammatory Bowel Disease
- Galectins and Cancer Biology
- Pharmacological Effects of Natural Compounds
- Microscopic Colitis
- Colorectal Cancer Screening and Detection
- Autoimmune and Inflammatory Disorders
- Eosinophilic Esophagitis
- Mycobacterium research and diagnosis
- Helicobacter pylori-related gastroenterology studies
- Liver Diseases and Immunity
- Immunodeficiency and Autoimmune Disorders
- Colorectal Cancer Treatments and Studies
- Hidradenitis Suppurativa and Treatments
- Gastrointestinal Bleeding Diagnosis and Treatment
- Empathy and Medical Education
- Gastric Cancer Management and Outcomes
- Chronic Lymphocytic Leukemia Research
- Food Allergy and Anaphylaxis Research
- Patient-Provider Communication in Healthcare
- Pregnancy and Medication Impact
- Drug-Induced Adverse Reactions
- Pancreatitis Pathology and Treatment
- Systemic Lupus Erythematosus Research
- Veterinary medicine and infectious diseases
- Abdominal vascular conditions and treatments
Kitasato Institute Hospital
2020-2024
University of Chicago
2023-2024
Kitasato University
2020-2024
Jichi Medical University
2006
Leucine-rich α-2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during acute phase has not been enough investigated.
Summary Background Bowel ultrasonography is a non‐invasive imaging tool that can repeatedly monitor ulcerative colitis (UC) activity. Aim This study aimed to determine whether early transabdominal or transperineal changes predict subsequent clinical response induction therapy in patients with UC. Methods single‐centre prospective explored ultrasonographic predictors for remission (patient‐reported outcome‐2 ≤ 1 no rectal bleeding subscore) at week 8 active UC who underwent therapy,...
Introduction: A large proportion of small bowel lesions in Crohn’s disease (CD) may exist beyond the reach ileocolonoscopy and there is no gold standard imaging modality to screen them, suggesting need for optimal biomarkers. We aimed compare usefulness C-reactive protein (CRP), faecal calprotectin (FC), leucine-rich alpha-2 glycoprotein (LRG) determining CD. Methods: This was a cross-sectional observational study. CRP, FC, LRG were prospectively measured patients with quiescent CD who...
Summary Background Endoscopic healing (EH) is a therapeutic target in ulcerative colitis (UC). However, even patients who have achieved EH relapse frequently. Aims To investigate the association between recent steroid use and risk UC with EH. Methods This multi‐centre cohort study included 1212 confirmed (Mayo endoscopic subscore ≤1). We excluded current systemic or history of advanced therapy. divided into group (last within 1 year; n = 59) non‐recent steroid‐naïve ( 1153). followed for 2...
Lymphocytic colitis is a microscopic characterized endoscopically by nearly normal-appearing colonic mucosa and histology demonstrating intraepithelial lymphocytosis. Microscopic that refractory to conventional therapies, including budesonide, rare but challenging with scarce evidence. Upadacitinib novel Janus kinase 1 selective inhibitor approved the US Food Drug Administration for atopic dermatitis, rheumatoid arthritis, psoriatic ankylosing spondylitis, moderately severely active...
Abstract Background and Aim The usefulness of second‐generation colon capsule endoscopy (CCE2) in ulcerative colitis (UC), especially clinically inactive patients, has been reported. Capsule Scoring Ulcerative Colitis (CSUC) was developed as a severity index for UC. We aimed to determine whether CSUC is useful predicting relapse during clinical remission. Methods Forty‐one UC patients remission who underwent CCE2 were prospectively registered from April 2016 August 2019. Patients' score...
Microscopic colitis has been increasingly recognized as a cause of chronic diarrhoea. We aimed to characterize the role disease-related factors and treatments on clinical outcomes microscopic colitis.
Mucosal healing is a treatment target for patients with ulcerative colitis. However, the relevance of proactive residual inflammation limited to distal colon unclear.Patients colitis who had extensive in clinical remission and underwent colonoscopy were retrospectively enrolled followed up 2 years. Patients complete endoscopic (CER; Mayo subscore [MES] 0) those short-segment (SS; active only sigmoid and/or rectum proximal MES compared incidence minor (only symptomatic) major (need induction...
Bowel ultrasound is a noninvasive alternative to endoscopy for assessing the disease activity of ulcerative colitis; however, it unclear whether bowel can predict subsequent relapse from remission.A retrospective cohort study enrolled patients with colitis who underwent between July 2018 and 2021 during clinical remission (patient-reported outcome-2 ≤1 no rectal bleeding) at least 3 months were followed up 1 year. Ultrasonographic findings (bowel wall thickness, flow, stratification,...
Lay Summary We describe the first reported case of a nonmedically trained patient using handheld ultrasound device to monitor his ulcerative colitis in real time at home during induction therapy for severe colitis.
Health anxiety has many damaging effects on patients with chronic illness. Physicians are often unable to alleviate concerns related living a disease that an impact daily life, and unregulated websites can overrepresent extreme anxiety-inducing outcomes. Educational clinician video interventions have shown some success as acute anxiolytic in health settings. However, little research evaluated if peer-based would be feasible alternative or improvement.This pilot study assesses the efficacy of...
Abstract Background Approximately 2% of patients with inflammatory bowel disease (IBD) have concurrent primary sclerosing cholangitis (PSC). Liver transplantation (LT) is sometimes required due to progressive PSC. However, the management active IBD post-LT challenged concomitant anti-rejection immunotherapies. Janus kinase inhibition has been previously described properties in who had renal transplants. Here, we describe our experience upadacitinib (UPA), a selective kinase-1 inhibitor, for...
Abstract Background Ulcerative colitis (UC) often leads to hospitalization and may be resistant standard treatments, necessitating colectomy. Upadacitinib (UPA), an oral selective Janus kinase 1 inhibitor, offers a novel mechanism the benefit of rapid predictable pharmacokinetics which suggest it efficacious in acute severe UC (ASUC). However, there are limited number cases using different dosing regimens describing potential this treatment for ASUC. We describe efficacy safety UPA...